论文部分内容阅读
目的 探讨13 1I标记人源抗乙肝表面抗原单克隆抗体Fab片段 (抗HBsFab)瘤内给药治疗荷人肝癌裸鼠移植瘤的合理性。方法 荷瘤裸鼠分为 5组 ,分别经瘤内注射13 1I 抗HBsFab、13 1I 无关Fab、13 1I、PBS及腹腔注射13 1I 抗HBsFab。 5d后每组各取 2只作组织分布测定 ,其余观察 3周 ,计算各组肿瘤生长抑制率。结果 瘤内注射13 1I 抗HBsFab组放射性计数瘤 /肝比值是腹腔注射组的 9倍 ,3周后前者肿瘤生长抑制率高于后者 ,分别为 62 .3%和 46.7%。结论 采用瘤内注射13 1I标记人源抗HBsFab导向治疗肝癌 ,具有低毒高效的治疗作用 ,临床实用价值大
Objective To investigate the rationality of intratumoral administration of 13 1I-labeled human anti-hepatitis B surface antigen Fab fragment (anti-HBsFab) in the treatment of human hepatoma bearing nude mice. Methods Tumor-bearing nude mice were divided into 5 groups and injected intratumorally with 13 1I anti-HBsFab, 13 1I-independent Fab, 13 1I, PBS and intraperitoneal injection of 13 1I anti-HBsFab. After 5 days, 2 rats in each group were taken for tissue distribution measurement, and the rest were observed for 3 weeks. Tumor growth inhibition rates were calculated for each group. RESULTS: The tumor count/hepatic ratio of intratumoral injection of 131I anti-HBsFab was 9 times that of the intraperitoneal injection group. After 3 weeks, the tumor growth inhibition rate of the former was higher than that of the latter, which was 62.3% and 46.7%, respectively. Conclusion Intratumoral injection of 131I-labeled human anti-HBsFab for the treatment of liver cancer has a low toxicity and highly effective therapeutic effect.